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Expression of p210ber'ab' by Metallothionein Promoter Induced T-cell Leukemia in Transgenic Mice
By Hiroaki Honda, Takeshi Fujii, Masaaki Takatoku, Hiroyuki Mano, Owen N. Witte, Yoshio Yazaki, and Hisamaru Hirai
The ~2 1 0~~~' chimeric protein is considered to be implicated in the pathogenesis of Philadelphia chromosome-positive human leukemias. To investigate its biologic function in vivo, we generated transgenic mice expressing ~2 1 0~~~~ driven by the metallothionein enhancerlpromoter. Two of six founder mice and the transgenic progeny developed leukemias several months after birth. In the leukemic tissues, the expression of the ~2 1 0~~' " transgene product was detected and the increased tyrosine-phosphorylation of cellular proteins was observed. The expressed ~2 1 0~/ '~' transgene product was shown to possess an enhanced kinase activity. The leukemic cells showed rearrangements in the T-cell receptor loci, indicating that the leukemic cells were monoclonal and committed to the T-cell lineage. Poly-HE PHILADELPHIA chromosome (Phl) is the cytogenetic hallmark associated with chronic myelogenous leukemia (CML) and a significant number of de novo acute lymphoblastic leukemias (ALLs).' It represents a reciprocal translocation between chromosomes 9 and 22, t(9;22) (q34;qll): where the c-ab1 proto-oncogene on chromosome 9 is translocated to the 5.8-kb region on chromosome 22, denoted as the breakpoint cluster region ( b~r ) .~
In the resulting bcr/abl chimeric gene, the N-terminal segment of cab1 oncogene is replaced by a bcr-derived ~equence?~ as observed in the case of v-abl, in which the normal N-terminus of c-ab1 is replaced by the viral gag-derived sequence. 6 Two bcr/abl chimeric proteins having different molecular weights are produced depending on the translocation juxtap~sition.~.~-" The larger chimeric product, p21ObC"&', contains either 902 or 927 bcr-derived amino acid residues and is observed in almost all cases of CML,3-5 whereas the smaller form, p19P'&', includes only 436 bcr-derived amino acids fused to the same portion of c-ab1 and is mainly associated with ALL."" Both chimeric proteins possess an enhanced tyrosine kinase activity in comparison with the normal c-ab1 product and are thus considered to be implicated in the pathogenesis of Ph'-positive human leukemias.'* To better understand the pathogenic processes caused by the bcr/abl chimeric protein in vivo, it seems to be necessary to establish animal models that express p21p''b' or p190""' " and develop hematologic malignancies. Several different approaches have been made to create the animal models, including virus-mediated gene transfer, the use of transgenic mice, and direct viral injection.
Daley et all3 reconstituted lethally irradiated mice with bone mamow cells infected with p210bc/"b'-containing retroviruses and showed that some of the recipient mice developed hematologic malignancies. The reconstituted mice exhibited three different types of hematologic malignancies, including granulocytic hyperplasias with maturation resembling human CML, acute lymphoblastic leukemias, and tumors of macrophage cell types. DNA analysis showed that a limited number of the infected cells had differentiated and reconstituted the different hematopoietic cell series. Other studies also using lethally irradiated syngeneic recipient mice transplanted with p2 10bcr'ob'-expressing bone marrow cells showed that the recipient mice developed various types of hematologic disorders such as granulocytic leukemias, myelomonocytic leukemias, pre-B-and T-cell lymphomas, reticulum cell sarcomas, and erythroid tumor^.'^.'^ These results indicate that a progenitor stem cell infected with p210bcr'ab'-containing retrovirus acquired a proliferative advantage and resulted in casing various types of hematologic malignancies.
On the other hand, the transgenic mouse is an alternative and useful approach to investigate the biologic function of bcr/abl chimeric gene product in vivo. Heisterkamp et all6 generated transgenic mice expressing ~1 9 P '~~' driven by metallothionein promoter and showed that 8 of 10 founder mice developed hematologic neoplasms within a short period after birth. Six mice showed a splenic enlargement involved with neoplastic lymphoblasts, whereas 2 other mice exhibited myeloid proliferation with a marked infiltration in the central nervous system, resembling human ALL or CML blast crisis, respectively. Subsequently, Hariharan et a l l 7 microinjected a fusion gene of bcr and v-ab1 coupled with either the Ig heavy-chain enhancer (Ep) or the part of the long Histopathologic studies. When the mice were found dead or moribund, the peripheral blood of the mice was strained with WrightGiemsa (WG). When the mice were autopsied or killed, tissues were fixed in a buffered formalin and stained with hematoxylin-eosin (HE).
Western blot analysis. Tissues were homogenized in the RIPA lysis buffer (150 mmol/L NaCI, 50 mmol/L Tris-Cl [pH 7.41, I % Triton X-100, 0.05% SDS, and 1% sodium deoxycholate) with 50 U/mL aprotinin. For detecting the p210"r' ' h' transgene product, 1 0 0 pg of proteins extracted from thymus, spleen, and liver of a leukemic mouse or a nontransgenic control was separated by SDS-polyacrylamide gel electrophoresis 7.5% (SDS-PAGE) with a molecular weight protein marker (Bio-Rad, Richmond, CA), transferred to a polyvinylidene membrane (Immobilon; Millipore, Yonezawa, Japan), and probed with 1:200 diluted anti-c-ab1 monoclonal antibody (MoAb) AB3 (Oncogene Science, Manhasset, NY). For detecting tyrosine-phosphorylated proteins, 1 0 0 pg of proteins extracted from thymus, spleen, and liver of a leukemic mouse or a nontransgenic control was separated by 7.5% SDS-PAGE with a molecular weight protein marker, transferred to a polyvinylidene membrane, and probed with antiphosphotyrosine MoAb, 4G10, according to the manufacturer's instructions.2'
In vitro immunecomplex kinase assay. One milligram of proteins extracted from thymus, spleen, and liver of a leukemic mouse or a nontransgenic control was incubated with 1:200 diluted AB3, followed by antimouse rat IgG (Sigma, St Louis, MO) and protein A (Sigma). The immunoprecipitated proteins were washed five times with the lysis buffer, followed by five washes with the kinase buffer (50 mmol/L Tris-C1 [pH 7.41, 10 mmol/L MgCI2, and 10 mmol/L MnC12), and incubated with 10 pCi of y"P-ATP (Amersham. Bucks, UK) at room temperature for 15 minutes. The phosphorylated proteins were separated by 7.5% SDS-PAGE with a molecular weight protein marker, dried, and autoradiographed.
DNA analysis of leukemic cells. High molecular weight DNAs were extracted from thymi of leukemic mice or a nontransgenic control as previously described.22 Ten micrograms of DNAs was digested with appropriate restriction enzymes (Takara), separated in a 0.7% agarose gel, transferred to a Nylon membrane (Hybond-N; Amersham), and hybridized with mouse TCRP or TCRy probe. Hybridization and washing conditions were the same as described above. The signals were detected with Kodak XAR films (Kodak) or using Fuji image analyzer (Fujix bas 2000; Fujifilm).
RNA exrracrion and polymerase chain reaction (PCR) amplification. Total RNAs were extracted from the tissues of a transgenic mouse of each line using the acid guanidine/phenol-chloroform method. 23 The methods of reverse transcription and PCR reaction have been described p r e v i~u s l y .~~ To distinguish the PCR product of genomic amplification from that of mRNA amplification by the molecular weights, the primers (PI-P4) were placed encompassing the SV40 splicing signal (see Fig 1) . K-ras PCR was also performed as an internal control. terminal repeat (LTR) of the myeloproliferative sarcoma virus (MPSV) and generated transgenic mice expressing p2 1 Ok""'"". They reported that pre-B -or T-cell lymphomas were developed in some of the transgenic mice bearing either construct after a variable latent period.
An alternative approach is to inject bcr/abl-expressing virus directly into a mouse body. Clark et allR injected p 19p'"h'-or p2 1 p'"'-expressing retroviruses intrathymically into mice and showed that mice injected with retroviruses expressing both types of chimeric proteins developed thymomas after a relatively long latent period.
Despite the previous studies described above, there have been no reports concerning mice transgenic for p21""/' "' ' ' , the chimeric protein that is most significantly implicated in Ph'-positive human leukemias. To address this problem, we generated transgenic mice expressing p210k'/"*' by the metallothionein enhancerlpromoter and investigated the oncogenicity of p210h"/"" using the transgenic mice.
MATERIALS AND METHODS
Generation of 1UT/p210m''~l transgenic mice. The ret cDNA in pMT/ret" was removed with Sma I digestion (Takara, Kyoto, Japan) and replaced by bcrlabl (p210) cDNA (b3a2 type) to give the construct pMT/bcr/abl (~210). The DNA fragment encompassing the metallothionein-I enhancerlpromoter, bcr/abl (p2 10) cDNA, and the SV40 early splicing and polyadenylation signals was excised, purified, and used for microinjection. The schematic model of the injection fragment is shown in Fig 1. The fragment was microinjected into pronuclei of eggs from C57BU6XDBA/2 F2 mice (Clea, Tokyo, Japan), and the microinjected eggs were transferred to ovarian ducts of pseudo-pregnant recipients. The method of microinjection and embryonal transfer was essentially described previously.2o Transgenic mice were identified by hybridizing the DNAs obtained by tail cut biopsy with the injection fragment as a probe. The hybridization was performed in a solution containing 50% formamide, 5X SSC (IX SSC: 150 mmol/L NaCI, 15 mmoVL Na-citrate), 5X Denhart's solution (1 mg/mL polyvinylpyrrolidone, 1 mg/mL bovine serum albumin, and 1 mglmL Ficoll), 0.5% sodium dodecyl sulfate (SDS), 50 mmol/L Tris-C1 (pH 7.4). 100 ng/mL salmon sperm DNA, and "P-labeled injection fragment at 42°C for overnight. The filters were washed twice in 2X SSC/O.I% SDS at 55°C for 20 minutes and then twice in 0.2X SSC/O.I% SDS at 55°C for 20 minutes. The signals were detected with Kodak XAR Films (Kodak, Rochester, NY) or using Fujix Bas 2000 image analyzer (Fujix bas 2000; Fujifilm, Kanagawa, Japan).
RESULTS
Leukemias in MT/p210b"l"'' transgenic mice. We generated six founder mice carrying 5 to 10 copies of the transgene use only. in a tandem manner (data not shown). All founder mice grew with no abnormal findings until approximately 3 months after birth, when a founder mouse, named MT/bcr/abU2-21, was discovered to be dead. The macroscopic appearance of MT/bcr/abU2-21 exhibited a thymic enlargement and a marked splenomegaly. Staining of peripheral blood with WG showed excessively proliferated blast cells with no granules, having an appearance of lymphoblasts. Pathologic examination showed that leukemic cells were infiltrated in all tissues examined, especially in thymus, spleen, and liver. Several weeks after the death of MT/bcr/abU2-21, another founder mouse, named MThcdabU2-23, was found to be moribund. The white blood cell (WBC) count of MTlbcrlabU2-23 was elevated to 3 X 104/pL, and the WG staining of peripheral blood showed a proliferation of blast cells, also having a morphologic appearance of lymphoblasts (Fig 2A) . When MT/bcr/abU2-23 was killed, almost the same morphologic appearance as that of MT/bcr/abU2-21 was observed, except that MT/bcr/abU2-23 carried subcutaneal lymph node swellings. The macroscopic appearance of MTlbcrlabU2-23 when killed is shown in Fig 3. Pathologic analysis also showed that leukemic cells were infiltrated in all tissues examined, especially in thymus, spleen, and liver (Fig 2B, C , and D, respectively). MT/bcr/abU2-21 died sterile, whereas MT/bcr/ abU2-23 transmitted the transgene to its progeny and, to date, approximately one third of the transgenic progeny developed leukemias (Fig 4) . All leukemic progeny mice showed almost the same morphologic appearance as those of two founder leukemic mice, namely a thymic enlargement, a massive splenomegaly, and/or lymph node swellings ( Table  1) .
Expression of p210b""bl transgene product and increased tyrosine-phosphorylation of cellular proteins in leukemic tissues. To confirm that leukemias developed in transgenic mice were associated with the expression of the ~210b"/"~' transgene product, proteins extracted from thymus, spleen, and liver of a leukemic founder mouse, MT/bcr/abU2-23, were probed with anti-c-ab1 MoAb, AB3. As shown in Fig  5 (left panel) , the expression of the p210bcr'ab' transgene product was detected in the tissues examined. In addition, the finding that the expression level of the ~2 1 0~"~~' was consistent with the proportion of the leukemic cells infiltrated indicates that the p210b"r/"b' was produced by the infiltrated leukemic cells. We also investigated tyrosine-phosphorylation of cellular proteins affected by the expression of ~2 1 p "~' . Proteins extracted from the same tissues of MT/bcr/abU2-23 were probed with antiphosphotyrosine antibody, 4G10. As shown in Fig 5 (right panel) , a number of cellular proteins with increased tyrosine-phosphorylation were observed in MT/bcr/abU2-23 in comparison with nontransgenic control, suggesting that expression of p210kr/"b' induced tyrosinephosphorylation of other cellular proteins. The band of 210 kD (indicated by an arrow in the right panel of Fig 5) was considered to be the autophosphorylated p2 lobe"&', because a band of the same molecular weight was detected by immunoprecipitating cellular proteins with AB3 and probing the immunoprecipitated proteins with 4G10 (data not shown). As for the leukemic transgenic progeny of MT/bcr/abU2-23, the expression of ~2106"/"~' and increased tyrosine-phosphorylation of cellular proteins were also observed in the leukemic tissues (data not shown).
Kinme activity of p218"'"b' transgene product. p2lP'& has been shown to have an enhanced tyrosine kinase activity in comparison with normal c-ab1 proto-oncogene product." To examine whether the p21P'&' transgene product contained an enzymatically active kinase activity, the in vitro immunecomplex kinase assay was performed using proteins extracted from thymus, spleen, and liver of MT/bcr/abl/2-23 or a nontransgenic control. As shown in Fig 6 , the autophosphorylated ~2106c"~' (indicated by an arrow) and other phosphorylated cellular proteins were observed in the leukemic tissues. This result indicates that p21P'&' transgene product contained an enhanced kinase activity, which would contribute to the leukemogenesis observed in p210b""Ob' leukemic mice.
Clonality and cell lineage of the leukemic cells. All the leukemic mice showed a thymic enlargement, suggesting that the leukemias developed in MT/bcr/abl transgenic mice were T-cell leukemias. To determine the monoclonality and cell lineage of the leukemic cells, Southern blot analysis for gene rearrangement of TCRP or TCRy region was performed. The DNAs extracted from thymi of MT/bcr/abU 2-21, MT/bcr/abY2-23, and a nontransgenic control were digested with EcoRI, BamHI, or Hindm and were hybridized with mouse TCRp or TCRy region as a probe. As shown in Fig 7, leukemic cells in both founder mice carried rearrangements at the p and y loci of the T-cell receptor gene.
Leukemic progeny mice also showed rearrangements in TCRp and TCRy regions (Table l), indicating that leukemias developed in MT/bcr/abl transgenic mice were clonal and committed to T-cell lineage. These results are consistent with the observation that leukemic cells expressed Thy-1.2 antigen at a high intensity demonstrated by the flow cytometry analysis (data not shown).
Tissue distribution of p2IObc"Bbl in the transgenic lines. To examine the tissue distribution of the ~2 l P ' "~' transgene product in the transgenic lines, RT-PCR was performed. Transgenic progeny of the line 2-23 that has reproducibly developed leukemias and the lines 2-18, 2-26, and 3-9 that have not developed leukemia were used for this experiment. The transgenic line 5-5 was sterile and was excluded from this experiment. RNAs extracted from brain, thymus, lung, heart, liver, spleen, kidney, and bone marrow of a transgenic mouse of each line were subjected to RT-PCR. The PCR product of genomic amplification is approximately 230 bp, whereas that of mRNA amplification is approximately 160 bp, because 70 bp is removed by the splicing (see Fig 1) . The result is shown in Fig 8. In the line 2-18, transgene expression was observed only in kidney. In the line 2-26, no transgene expression was observed in all tissues examined. In the line 3-9, transgene expression was detected in kidney and weakly in brain. In the line 2-23, in contrast to other transgenic lines, transgene expression was observed in almost all tissues except bone marrow, and high expression was observed in thymus and heart.
DISCUSSION
Previous reports showed that ~2106"/"~' is implicated in the pathogenesis of hematologic malignancies in vivo using use only. use only.
For personal at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From Fig 2. (Cont'd) I.? mice that were lethally irradiated and reconstituted with p210kdd'-expressing bone marrow cell^'^"^^^'** or using mice that were injected with p2ICFd'-expressing retroviruses intrathymically.'8 However, there have so far been no reports showing the oncogenicity of p210kr'*' by means of transgenic mice. We attempted to clarify this issue by creating transgenic mice expressing ~2 l P ' '~' driven by the metallothionein enhancer/promoter. We used the metallothionein enhancer/promoter as a regulatory element for two reasons. (1) Previous studies showed that the metallothionein promoter works efficiently in transgenic mice bearing transgenes that are activated by chromosomal translocations such as ~1 9 p ' " '~ and ret oncogene." (2) Because the bcr/ ab1 construct under the control of the bcr gene promoter renders a lethality during embryogenesis in transgenic mice,16 a weak and inducible promoter might be preferable for generating p21ob"/"b' transgenic mice.
As a result, we generated six transgenic founder mice carrying 5 to 10 transgene copies. Among them, two founder mice, MT/bcr/abl/2-21 and MT/bcr/abl/2-23, developed leukemias approximately 3 months after birth (Table 1) . Because transgenes are expected to be integrated in different chromosomes in different transgenic lines,= the fact that two founder mice developed the same disease strongly suggests that the disease was not caused by the loss of function of the integration site but by the biologic effect of the transgene product. Indeed, the expression of the p2lp'&' transgene product was detected in the tissues in which leukemic cells inliltrated.
To investigate the expression of p210k"d' transgene product in each transgenic line, we initially performed the Western and Northern blot analyses. However, we could not detect ~2 1 0~~'~' protein or mRNA in any tissues examined, probably because of the low expression level of the transgene driven by the metallothionein promoter (data not shown). in a variety of tissues, as expected from the characteristics of the metallothionein promoter.'" The findings that the IS expressed in various tissues but tumors so far developed have been restricted to the hematopoietic lineage may provide an additional evidence that the tumorigenicity of bcrkabl chimeric gene products is specific for the hematopoietic cells, as suggested in the cases of pl90"'"~'"' transgenic mice:" Considering the oncogenic specificity of p210""r~"h' to the hematopoietic tissues, it might be reasonable that leukemias have developed only in line 2-23, because 2-23 is the only line expressing p210""~""' in the hematopoietic tissues such as thymus and spleen (Fig 8) . The reason why all of the leukemic mice in the line 2-23 exhibited T-cell phenotype is not clear; however, one possibility is that the transgene was relatively highly expressed in thymus, in which gene rearrangements frequently occur. An additional event enhancing p2 I0"'"~'''' expression in thymus might cause T-cell proliferation and result in developing T-cell leukemia. We investigated whether the transgene was rearranged in the
HONDA ET AL tumor tissues by the Southern blot analysis, but no obvious rearrangement was detected (data not shown).
MT/bcr/abl transgenic mice reproducibly developed T-cell leukemias. In previous transgenic studies, p190"""'" transgenic mice developed lymphoblastic leukemias"." and lymphoma^.'^ Why bcr/abl transgenic mice generated so far have not been able to exhibit granulocytic hyperplasia as observed in mice that were lethally irradiated and reconstituted with bcr/abl-expressing bone marrow cells remains unclear. but one possibility could be the differences in the mouse strains used. Previous reports showed that mouse strains have a marked influence for susceptibility to specific tumor type^.".'^ In the cases of bone marrow reconstitution, almost all of the experiments have been performed using Balb/c strain for donor and recipient mi~e"'~~""~-, on the other hand, cross-hybrid mice have been used for generating transgenic mice (CS7BU6XCBA2 for p190h"r~""', CS7BW 6XSJL for p210'~r~""'h', and C57BW6XDBA2 for p21 O"' /"' ' in our ~tudy).'".'~ However, Elefancy et all4 used either C57BW6 or DBA2 strain for bone marrow reconstitution and showed that several different hematologic malignancies, including macrophage tumors, erythroid tumors, and pre-Band T-cell lymphomas, were observed in each mouse strain. Therefore, the mouse strain used might not be a reason. Another possibility is that the transgene might be more frequently activated in lymphoid progenitors rather than in myeloid progenitors or that progenitor cells bearing the transgene are more likely to develop lymphoid malignancies rather than myeloid malignancies. An extensive p210'"''/"''' transgenic study using other promoters might clarify the issue concerning lymphoid predominance in tumor development in transgenic mice.
The terminal stage of CML, namely blast crisis, is sometimes difficult to distinguish from de novo leukemia. From this point of view, it is worth investigating whether the Tcell leukemias developed in p210""/""' transgenic mice are either de novo acute T-cell leukemias or T-cell crises of CML. We believe that they are more likely to be de novo p2 1 ~/"r/v.""' transgenic mice developed pre-B-and T-cell T-cell leukemias, because no granulocytic hyperplasia existed or proceeded in p210hrr/""' transgenic mice until they developed overt leukemias, and T-cell involvement in CML crisis is extremely rare.3J
In clinical courses of Phi-positive patients, p210k"""' is found in almost all cases of CML, which initially begins as an indolent disease characterized by the proliferated myeloid with ALL:"' which is a more aggressive malignancy of early lymphoid precursors. To directly compare the lineage specificity and transforming potential of pl90"'~"''''' with those I n vivo, Kelliher et al" used mice that were lethally irradiated and reconstituted with stem cell population infected with either p190"""""-or p210h"""-expressing retroviruses. They showed that, although both types of recipient mice exhibited a similar spectrum of diseases, the mice receiving pl 90h'"~"h'-infected progenitors develop a more aggressive disease after a shorter latent period than do the mice treated with p21Ob'""'"-infected cells. In cases of transgenic mice, the oncogenic activities of p19Obrr""" and p210"""'"' could be compared, because the same promoter (metallothionein) and almost the same cross-hybrid mice (CS7BU 6XCBA2 for pl90' ""' ' ' ' and CS7BU6XDBA2 for p210""/"") were used for generating transgenic mice." The result that p190""""' transgenic mice developed leukemias in a shorter period (within 58 days)" than did p210""' "' ' transgenic mice (approximately 2 to 4 months, see Table 1 were digested with EcoRI, BamHI, or Hindlll and were hybridized with mouse TCRp (left) or TCRy (right) as a probe. In the left panel, MT/bcr/ ab1/2-21 showed rearranged bands in each enzyme digestion, whereas MT/bcr/ab1/2-23 showed a germline pattern. However, the band intensities observed in MT/bcr/ab1/2-23 are approximately half of those observed in the nontransgenic control in each enzyme digestion, indicating that one allele was germline but another allele was rearranged. In the right panel, apparent rearranged bands are observed in both leukemic founder mice.
activities of other genes that might enhance or suppress p21 O".r' ' ' b' oncogenic potential. Furthermore, the p2 1 O"' "' h' transgenic mice would be used for evaluating the biologic effects of therapeutic reagents that are now or will be applied for Ph'-positive leukemic patients.
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